BridgeBio Pharma, Inc. $BBIO Shares Sold by HighTower Advisors LLC
HighTower Advisors LLC significantly reduced its stake in BridgeBio Pharma (NASDAQ:BBIO) by 94.6% in the third quarter, selling over 4 million shares and retaining 230,393 shares. This sale comes despite positive catalysts like strong Phase 3 results and analyst upgrades, which have set a consensus price target near $82. However, the optimism is somewhat countered by clustered insider selling, with Director Randal W. Scott and CFO Thomas Trimarchi among others selling a total of 176,121 shares valued at approximately $13 million over three months.
BridgeBio (BBIO) Shares Dip After UBS Summit Withdrawal
BridgeBio Pharma's shares dipped by 3% after the company withdrew from a major biotech conference. The company, which focuses on genetic disease treatments and has a market capitalization of $13.13 billion, has shown strong revenue growth but struggles with profitability and faces financial leverage concerns. Despite institutional confidence, an Altman Z-Score in the distress zone and significant insider selling indicate potential risks for investors.
16,893 Shares in BridgeBio Pharma, Inc. $BBIO Purchased by L & S Advisors Inc
L & S Advisors Inc. purchased a new stake of 16,893 shares in BridgeBio Pharma (NASDAQ:BBIO) during the third quarter, valued at approximately $877,000, contributing to institutional investors now holding 99.85% of the stock. While Wall Street analysts have a "Moderate Buy" consensus rating and an average target price of $82.05, recent clustered insider selling, including a director selling 10,000 shares and the CEO selling 40,000 shares, may exert downward pressure on sentiment. Despite positive sentiment from strong clinical trial results and analyst upgrades, the stock opened down approximately 4.3% at $70.72.
Skandinaviska Enskilda Banken AB publ Has $7.74 Million Stock Position in BridgeBio Pharma, Inc. $BBIO
Skandinaviska Enskilda Banken AB publ significantly increased its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO) by 152.1% in Q3, now holding shares worth approximately $7.74 million. Despite this institutional accumulation, the stock has experienced recent volatility due to clustered insider selling totaling over $13 million, including sales by the CEO and CFO. Analysts maintain a largely positive outlook with an average target price of $82.05, bolstered by strong Phase 3 results, though an upcoming earnings call and ongoing insider sales contribute to short-term fluctuations.
Bank of America Securities Sticks to Its Buy Rating for BridgeBio Pharma (BBIO)
Bank of America Securities analyst Jason Zemansky has reiterated a Buy rating for BridgeBio Pharma (BBIO) with a $97.00 price target. This aligns with a strong Buy consensus among analysts, targeting an average of $101.13. Despite the positive analyst sentiment, corporate insider activity shows a negative trend, with increased selling of BBIO shares by insiders in the last quarter.
BridgeBio Pharma CAO Apuli sells $37898 in BBIO stock
BridgeBio Pharma's Chief Accounting Officer, Maricel Apuli, sold 510 shares of common stock for $37,898 and disposed of 4,349 shares to cover tax obligations. These transactions come as BridgeBio Pharma recently announced positive Phase 3 trial results for its achondroplasia treatment, infigratinib, leading to increased price targets from analysts and a $550 million convertible senior notes offering.
NEOS Investment Management LLC Has $5.02 Million Stock Holdings in BridgeBio Pharma, Inc. $BBIO
NEOS Investment Management LLC decreased its stake in BridgeBio Pharma, Inc. by 21.9% in Q3, now holding 96,561 shares valued at approximately $5.02 million. Despite this, Wall Street analysts maintain a largely bullish outlook with a consensus "Moderate Buy" rating and an average price target of $82.05, though significant insider selling, including by the CEO and CFO, could impact investor sentiment. BridgeBio Pharma, a clinical-stage biopharmaceutical company, is focused on developing therapies for genetic diseases and cancers.
BridgeBio earnings up next: Can pipeline wins fuel growth?
BridgeBio Pharma Inc. is set to release its Q4 and full-year 2025 earnings, with analysts expecting a significant improvement in financials and maintaining a "strong buy" rating for the stock. Investors will focus on the commercial performance of Attruby, progress in the pipeline with drugs like infigratinib for achondroplasia, and the company's operating leverage and cash runway as it aims for profitability. The report will assess if BridgeBio's decentralized drug development model can lead to scalable and profitable growth, potentially positioning it as a major biotech player.
A Look At BridgeBio Pharma (BBIO) Valuation After Positive Phase 3 PROPEL 3 Achondroplasia Results
BridgeBio Pharma (BBIO) has shown significant growth with positive Phase 3 trial results for its achondroplasia drug, infigratinib, and a strong 1-year total shareholder return of 113.72%. Simply Wall St's analysis suggests the company is undervalued, with a fair value of $89.79 against a current price of $75.85, although its high P/S ratio indicates potential valuation risk. Investors are advised to consider both the growth potential from its late-stage pipeline and the inherent risks associated with a loss-making biotech.
BoFA Notes BridgeBio Pharma, Inc. (BBIO)’s Upcoming Q4 Earnings May Have Limited Market Impact
Bank of America analyst Jason Zemansky raised the price target for BridgeBio Pharma, Inc. (BBIO) to $88, maintaining a Buy rating, but noted that upcoming Q4 earnings may have limited market impact due to prior announcements. Barclays also initiated coverage with an Overweight rating and a $157 price target, citing growth potential in the biotech industry. The article highlights BBIO as an innovative biopharmaceutical company focused on genetic diseases, while also promoting an AI stock as a potentially more promising investment.
BoFA Notes BridgeBio Pharma, Inc. (BBIO)’s Upcoming Q4 Earnings May Have Limited Market Impact
Bank of America analyst Jason Zemansky raised the price target for BridgeBio Pharma, Inc. (BBIO) to $88 from $85, maintaining a Buy rating. However, BoFA suggests that the upcoming Q4 earnings report for BBIO may have a limited market impact due to prior pre-announcements. Barclays also initiated coverage on BBIO with an Overweight rating and a $157 price target, citing optimistic growth potential for the biotech industry in 2026.
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma, Inc. announced inducement grants of restricted stock units to 34 new employees, totaling 76,701 shares of common stock. These grants were approved by the compensation committee on February 12, 2026, and will vest over time, contingent upon continued employment. The awards were made in accordance with Nasdaq Listing Rule 5635(c)(4) to induce employment.
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma, Inc. announced incentive equity grants to 34 new employees, totaling 76,701 restricted stock units. These grants are part of an inducement material for employment, vesting over time, and comply with Nasdaq Listing Rule 5635(c)(4). BridgeBio aims to develop transformative medicines for genetic conditions through its decentralized model.
BridgeBio Pharma, Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
BridgeBio Pharma, Inc. (BBIO) will release its fourth quarter and full year 2025 financial results on February 24, 2026, after market close, followed by a conference call at 4:30 pm ET. The company, which focuses on developing medicines for genetic conditions, will also provide program updates during the call. A live webcast will be available on their investor relations website, with a replay accessible for 30 days.
BridgeBio to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 at 4:30 pm ET
BridgeBio Pharma, Inc. announced it will release its fourth quarter and full year 2025 financial results and business updates after the market closes on Tuesday, February 24, 2026. The company will host a conference call at 4:30 pm ET on the same day to discuss the results and program updates. Interested participants can access the live webcast via the "Events & Presentations" page on the BridgeBio website.
BridgeBio to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 at 4:30 pm ET
BridgeBio Pharma, Inc. announced it will release its fourth quarter and full year 2025 financial results and business updates after market close on Tuesday, February 24, 2026. The company will host a conference call at 4:30 pm ET on the same day to discuss these results and program updates. Interested parties can access the live webcast via the Investors section of BridgeBio's website.
Has BridgeBio Pharma (BBIO) Run Too Far After 112% One Year Share Price Surge?
BridgeBio Pharma (BBIO) has seen a significant 112% share price surge over the last year, prompting a valuation review. While a Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 74.0%, its Price-to-Sales (P/S) ratio of 40.99x indicates it is overvalued compared to its industry and a proprietary "Fair Ratio." The article presents bullish and bearish narratives to help investors understand the range of potential fair values for BBIO, emphasizing the importance of aligning investment decisions with individual assumptions about the company's future growth and risks.
BridgeBio’s Infigratinib Data Reframes Growth Story In Genetic Disorders
BridgeBio Pharma reported positive Phase 3 results for infigratinib in children with achondroplasia, meeting primary and secondary endpoints including improved height velocity and body proportionality. This marks a significant step for the company in genetic skeletal disorders and positions infigratinib as a potential anchor product. BridgeBio plans regulatory submissions in the U.S. and Europe in late 2026 and will accelerate development for related indications.
Why BridgeBio Pharma (BBIO) Is Up 10.6% After Breakthrough Phase 3 Infigratinib Data In Achondroplasia
BridgeBio Pharma's stock (BBIO) rose 10.6% following positive topline Phase 3 PROPEL 3 results for its oral drug infigratinib in children with achondroplasia. The drug demonstrated statistically significant gains in annualized height velocity and body proportionality, along with a favorable safety profile. BridgeBio plans to seek US and European approvals in the second half of 2026, which could significantly impact its late-stage pipeline and future growth.
BridgeBio Pharma (NASDAQ:BBIO) Given New $83.00 Price Target at Oppenheimer
Oppenheimer has increased its price target for BridgeBio Pharma (NASDAQ:BBIO) to $83.00, reiterating an "outperform" rating, following encouraging Phase 3 trial results for oral infigratinib. This aligns with other analyst upgrades and contributes to a "Moderate Buy" consensus. Despite positive clinical news, the article notes recent insider selling and potential negative earnings in the near term.
BridgeBio's Impressive Phase 3 Infigratinib Data Adds Competitive Pressure to BioMarin's Voxzogo
BridgeBio Pharma's impressive Phase 3 data for infigratinib is creating competitive pressure for BioMarin's drug, Voxzogo. BridgeBio is a biotechnology company focused on genetic research, with a pipeline targeting Mendelian disorders, precision oncology, and gene therapy, including four late-stage development programs. This report highlights the implications of their recent clinical trial success.
BridgeBio looks to challenge BioMarin in dwarfism market on Phase III win
BridgeBio's achondroplasia therapy, infigratinib, achieved primary and secondary endpoints in a Phase III trial, showing a significant increase in annualized height velocity and improvements in body proportionality. The company plans to seek regulatory approval in H2 2026, aiming to compete with BioMarin's Voxzogo and Ascendis Pharma's TransCon CNP. Infigratinib's oral administration offers a potential advantage over existing injectable treatments.
Jefferies Maintains Buy on BBIO BridgeBio Pharma, Inc. Feb 2026
Jefferies maintained its Buy rating on BridgeBio Pharma, Inc. (BBIO) and raised its price target from $85 to $100 on February 12, 2026, signaling increased optimism about the company's valuation based on updated fundamentals and trial data. Despite a -2.07% intraday dip in BBIO stock after the announcement due to profit-taking and market moves, the maintained Buy rating reinforces an expected upside case. Meyka AI gives BBIO a B+ grade, recommending investors monitor upcoming trial data and cash runway.
BridgeBio Pharma stock hits all-time high at 84.51 USD By Investing.com
BridgeBio Pharma Inc. (BBIO) stock reached an all-time high of $84.51, marking a significant 132.35% increase over the past year. This surge is supported by a market capitalization exceeding $14 billion, strong revenue growth of 62.46%, and a "Strong Buy" analyst consensus, despite some analyses suggesting it may be trading above its Fair Value. Recent positive Phase 3 trial results for its achondroplasia treatment, infigratinib, and a $550 million convertible senior notes offering further underscore investor confidence and strategic advancement.
BridgeBio Confident Infigratinib Can Steal Achondroplasia Market Share
BridgeBio announced positive topline results for its drug infigratinib in the PROPEL 3 trial for achondroplasia. The company is confident that this treatment will allow them to gain market share in the achondroplasia treatment landscape.
BridgeBio Pharma (NASDAQ:BBIO) CEO Neil Kumar Sells 40,000 Shares
BridgeBio Pharma CEO Neil Kumar recently sold 40,000 shares of the company's stock for $2.88 million, reducing his ownership by 5.44%. This sale follows several other substantial insider disposals, raising corporate governance concerns among some investors despite the company's positive Phase 3 trial results for oral infigratinib in achondroplasia. Analysts have largely maintained "buy" ratings on BBIO, with an average price target of $79.95, following these positive clinical updates.
BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026
BridgeBio Pharma's stock is soaring near its 52-week high after announcing positive results from its PROPEL 3 Phase 3 study of infigratinib for achondroplasia, a common form of dwarfism. The study showed significant improvements in annualized height velocity and proportionality compared to placebo, with no serious adverse events. BridgeBio plans to file for regulatory approval in the second half of 2026 and is expanding research for other rare indications.
BridgeBio Pharma (NASDAQ:BBIO) Reaches New 52-Week High - Here's What Happened
BridgeBio Pharma (BBIO) shares hit a new 52-week high after announcing positive Phase 3 results for its drug infigratinib for achondroplasia, with plans for regulatory submissions in H2 2026. The positive clinical data led to a significant stock jump and shifts in the competitive landscape. Despite potential for negative short-term earnings and notable insider selling, analysts maintain a "Moderate Buy" consensus.
BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026
BridgeBio Pharma Inc. (NASDAQ:BBIO) stock is nearing its 52-week high after reporting positive topline results from its PROPEL 3 Phase 3 pivotal study of oral infigratinib for achondroplasia, a form of dwarfism. The study showed significant improvements in annualized height velocity and proportionality compared to placebo. BridgeBio plans to file a New Drug Application and Marketing Authorization Application for infigratinib in the second half of 2026.
BridgeBio scores with dwarfism drug, setting up showdown with BioMarin, Ascendis
BridgeBio Pharma announced positive Phase 3 clinical trial results for its experimental drug, infigratinib, for achondroplasia, the most common type of dwarfism. The oral medication led to significantly increased annualized height velocity in children and was well-tolerated. These results position BridgeBio to compete with existing and soon-to-be-approved injectable treatments from BioMarin and Ascendis, potentially offering patients a less invasive alternative.
BridgeBio Pharma stock hits all-time high at 84.51 USD
BridgeBio Pharma (BBIO) stock reached an all-time high of $84.51, representing a 132.35% increase over the past year. This achievement is supported by a market capitalization exceeding $14 billion and a strong buy consensus from analysts. Recent positive Phase 3 trial results for infigratinib and a $550 million convertible senior notes offering further underscore the company's strong performance and investor confidence.
BridgeBio's oral drug boosts growth in children with dwarfism in late-stage trial
BridgeBio Pharma announced that its experimental oral therapy, infigratinib, significantly boosted growth rates in children with achondroplasia during a late-stage trial. The company plans to seek regulatory approval in the U.S. and Europe in the latter half of 2026, positioning this drug as a potential "game changer" due to its oral administration and superior efficacy compared to existing treatments. Analysts project the drug could achieve nearly $2 billion in peak annual sales.
BridgeBio posts trial win for dwarfism drug (BBIO:NASDAQ)
BridgeBio Pharma (BBIO) shares rose significantly in premarket trading after announcing successful topline data from a pivotal Phase 3 trial for its experimental dwarfism therapy, infigratinib. The drug targets achondroplasia, a form of dwarfism. The positive trial results mark a significant step for the Palo Alto-based biotech company.
BridgeBio Pharma Reports Positive Topline Results from PROPEL 3 Study of Oral Infigratinib in Children with Achondroplasia
BridgeBio Pharma announced positive topline results from its Phase 3 PROPEL 3 study for oral infigratinib in children with achondroplasia. The study met its primary endpoint, showing a statistically significant increase in annualized height velocity and the first significant improvement in body proportionality. The drug was well-tolerated, and BridgeBio plans to submit regulatory applications by late 2026, also accelerating development for hypochondroplasia.
BridgeBio Pharma (BBIO) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
BridgeBio Pharma (BBIO) is expected to report a year-over-year increase in earnings on higher revenues for Q4 2025, with an anticipated quarterly loss of $0.74 per share. However, the Zacks Earnings ESP of -2.69% combined with a Zacks Rank #3 makes it difficult to conclusively predict an earnings beat. Investors are advised to consider other factors beyond just earnings expectations.
Candriam S.C.A. Invests $7.74 Million in BridgeBio Pharma, Inc. $BBIO
Candriam S.C.A. acquired a new stake of $7.74 million in BridgeBio Pharma, Inc. (NASDAQ:BBIO) during the third quarter, purchasing 148,986 shares. Other institutional investors also adjusted their holdings in the company. Insider selling activity was noted, with significant share sales by a director and the CEO.
A Look At BridgeBio Pharma (BBIO) Valuation After Earnings Uncertainty Triggers A Sharp Share Price Decline
BridgeBio Pharma (BBIO) experienced a significant 15.24% drop following investor uncertainty ahead of its Q4 and full-year 2025 earnings report. Despite this, the company is considered undervalued by Simply Wall St's model, with a narrative fair value of approximately $89.79, largely due to its late-stage genetic disease pipeline. However, its high P/S ratio of 39.4x compared to industry averages suggests potential valuation risk if market sentiment shifts.
BridgeBio Pharma supports LGMD Family Guide distribution at conference
BridgeBio Pharma is actively distributing the LGMD Family Guide at the Treat-NMD International Conference, demonstrating its commitment to supporting the limb-girdle muscular dystrophy community. Attendees can access the guide by attending a presentation or collecting it from the company's team. This initiative aims to provide valuable resources and information to affected individuals and families.
Buy the Dip on This Biotech Stock After Recent Fall
BridgeBio Pharma Inc (NASDAQ:BBIO) stock recently experienced a sharp pullback from its record high after Pfizer withdrew a tafamidis patent in the EU. Despite this, the stock is currently up 5.2% and exhibits solid strength due to technical support, including its ascending 100-day moving average. Historical data suggests a high probability of gains one month after similar signals, with short interest building and a bullish put/call volume ratio potentially providing tailwinds.
BridgeBio Pharma (BBIO) Surges 6.8%: Is This an Indication of Further Gains?
BridgeBio Pharma's (BBIO) stock surged 6.8% likely due to promising late-stage clinical trial data for its investigational drug BBP-418 and the strong adoption of its marketed therapy, Attruby. The company also reported a solid cash position for 2025, ensuring funding for future clinical activities. Analysts expect significant revenue growth and a reduced quarterly loss for BBIO, with earnings estimates showing a positive revision trend.
BridgeBio Pharma (NASDAQ:BBIO) Shares Gap Up - Here's What Happened
BridgeBio Pharma (NASDAQ:BBIO) shares gapped up premarket, opening at $70.07. The company has a current market cap of $13.39 billion and is largely rated as a "Moderate Buy" by analysts, with an average price target of $79.05, following several recent target increases. Despite insider selling activity, institutional investors hold a significant majority of the company's stock.
BridgeBio (BBIO) Tumbles 15%, Mirrors Marked Bleed
BridgeBio Pharma Inc. (NASDAQ:BBIO) experienced a 15.24% stock decline on Thursday, closing at $63.73, attributed to a broader market downturn and investor pessimism following Bitcoin's significant drop. The company is expected to release its Q4 and full-year 2025 earnings on February 19, 2026. Despite the recent dip, Barclays and Morgan Stanley have assigned "overweight" ratings to BBIO with price targets indicating significant upside potential.
BridgeBio (BBIO) Tumbles 15%, Mirrors Marked Bleed
BridgeBio Pharma Inc. (NASDAQ:BBIO) experienced a 15.24% drop, closing at $63.73, on Thursday, mirroring a broader market decline and investor pessimism following Bitcoin's recent slump. The company is expected to release its Q4 and full-year 2025 earnings on February 19, 2026, and despite the recent tumble, it has received "overweight" ratings from Barclays and Morgan Stanley with price targets of $157 and $96, respectively. The article, however, pivots to promoting investment in AI stocks, suggesting they offer greater promise and higher returns than BBIO.
Y Intercept Hong Kong Ltd Has $724,000 Stock Holdings in BridgeBio Pharma, Inc. $BBIO
Y Intercept Hong Kong Ltd significantly reduced its stake in BridgeBio Pharma (NASDAQ:BBIO) by 93.4% in the third quarter, now holding $724,000 worth of shares. Despite this, analysts generally maintain a "Moderate Buy" rating with an average price target of $79.05, and some have recently raised their targets. Insider selling has also occurred, with executives disposing of shares totaling over $26 million, though insiders still own 18.20% of the company.
CORRECTING and REPLACING -- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma issued a corrected and replacing release regarding inducement grants under Nasdaq Listing Rule 5635(c)(4). The company announced that its compensation committee approved equity grants to 11 new employees, totaling 31,428 shares of common stock in restricted stock units. These grants were made under BridgeBio’s Amended and Restated 2019 Inducement Equity Plan as an inducement for new employment.
BridgeBio Pharma, Inc. $BBIO Shares Acquired by Federated Hermes Inc.
Federated Hermes Inc. significantly increased its stake in BridgeBio Pharma, Inc. (BBIO) by 53% in the third quarter, now owning 0.22% of the company valuing $22 million. Analysts maintain a "Moderate Buy" rating with a consensus price target of $79.05, despite the company missing Q3 EPS estimates but beating on revenue with substantial year-over-year growth. Insider selling has also been reported, with directors and CFO selling shares totaling over $26 million in the last 90 days.
Assessing BridgeBio Pharma (BBIO) Valuation After Recent Share Price Volatility
BridgeBio Pharma (BBIO) has seen recent share price volatility but strong performance over the last 3 months and year, prompting investors to scrutinize its valuation. Despite a recent pullback, the stock is showing a significant intrinsic discount estimated at 71.80% and trades about 20% below analyst targets. Simply Wall St's model suggests a fair value of $89.79, indicating it is undervalued, though this relies heavily on long-range assumptions for revenue, margins, and approvals of its genetic programs, particularly Attruby.
Barclays Initiates Coverage of BridgeBio Pharma (BBIO) with Overweight Recommendation
Barclays has initiated coverage of BridgeBio Pharma (BBIO) with an Overweight recommendation. Analysts forecast a 16.86% upside from its current price, with an average one-year price target of $90.56. Institutional ownership remains strong, with several major funds holding significant stakes despite some recent adjustments in their positions.
BridgeBio Pharma stock initiated with Overweight rating by Barclays
Barclays has initiated coverage on BridgeBio Pharma (NASDAQ:BBIO) with an Overweight rating and an $80.00 price target, citing the company's diversified late-stage portfolio and potential to become a large-cap biotech. Key drivers include upcoming Phase 3 achondroplasia data and growth from its Attruby treatment for ATTR-CM. This positive outlook is supported by recent strong revenue figures for Attruby and strategic financial moves, including a $550 million convertible senior notes offering.
BBIO Sees New Analyst Initiation with 'Overweight' Rating by Bar
Barclays has initiated coverage on BridgeBio Pharma (BBIO) with an 'Overweight' rating and set a new price target of $80.00. This follows several other analysts' positive ratings and price target increases for BBIO in late 2025 and early 2026. BridgeBio Pharma, a biotechnology company focused on genetic diseases, is seen by analysts as having a strong outlook, with an average target price of $89.57 and a consensus "Outperform" recommendation.
